DCM
IMCR icon

DAFNA Capital Management’s Immunocore IMCR Stock Holding History

DAFNA Capital Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-53,878
Closed -$1.61M – 93
2022
Q1 		$1.61M Buy
+53,878
New +$1.36M 0.42% 59

Other funds holding IMCR

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

DAFNA Capital Management's IMCR Position: Q2 2022 in Review

DAFNA Capital Management sold out of Immunocore (IMCR) in Q2 2022, closing a stake of 53,878 shares — an estimated $1.61M sold.

DAFNA Capital Management first reported a position in IMCR in Q1 2022 and held it in 1 quarter. The position peaked at $1.61M in Q1 2022. 66 funds tracked by Wall St. Rank hold IMCR as of Q2 2022.

  • DAFNA Capital Management reported no remaining Immunocore position as of Q2 2022 after selling out during the quarter.
  • DAFNA Capital Management sold 53,878 Immunocore shares in Q2 2022, an estimated $1.61M.
  • DAFNA Capital Management first reported a position in Immunocore in Q1 2022 and held it in 1 quarter.
  • DAFNA Capital Management's Immunocore position peaked at $1.61M in Q1 2022.
  • 66 funds tracked by Wall St. Rank held Immunocore as of Q2 2022.

Based on DAFNA Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.